Brenus Pharma secured an €11 million ($12.6 million) Series A extension and attracted its first APAC investor as it expands an in vivo immunotherapy platform for MSS metastatic colorectal cancer. The financing lifts Brenus’s total capital raised to about €38 million ($43.5 million) since inception. Investors included Sambrinvest, joining to strengthen Brenus’s European shareholder base, along with Korea Omega Investment Corp as the first institutional backing from the Asia-Pacific region. Brenus said the extension supports ongoing development of STC-1010 (NCT06934538), positioned for multi-asset platform expansion beyond a single program. The round signals that de-risking in early clinical stages continues to unlock follow-on funding, particularly when platform assets show a path to repeatable clinical differentiation.